Bronchodilator reversibility testing in chronic obstructive pulmonary disease

Calverley P M A; Burge P S; Spencer S; Anderson J A; Jones P W
August 2003
Thorax;Aug2003, Vol. 58 Issue 8, p659
Academic Journal
BACKGROUND: A limited or absent bronchodilator response is used to classify chronic obstructive pulmonary disease (COPD) and can determine the treatment offered. The reliability of the recommended response criteria and their relationship to disease progression has not been established. METHODS: 660 patients meeting European Respiratory Society (ERS) diagnostic criteria for irreversible COPD were studied. Spirometric parameters were measured on three occasions before and after salbutamol and ipratropium bromide sequentially or in combination over 2 months. Responses were classified using the American Thoracic Society/GOLD (ATS) and ERS criteria. Patients were followed for 3 years with post-bronchodilator FEV(1) and exacerbation history recorded 3 monthly and health status 6 monthly. RESULTS: FEV(1) increased significantly with each bronchodilator, a response that was normally distributed. Mean post-bronchodilator FEV(1) was reproducible between visits (intraclass correlation 0.93). The absolute change in FEV(1) was independent of the pre-bronchodilator value but the percentage change correlated with pre-bronchodilator FEV(1) (r=-0.44; p<0.0001). Using ATS criteria, 52.1% of patients changed responder status between visits compared with 38.2% using ERS criteria. Smoking status, atopy, and withdrawing inhaled corticosteroids were unrelated to bronchodilator response, as was the rate of decline in FEV(1), decline in health status, and exacerbation rate. CONCLUSION: In moderate to severe COPD bronchodilator responsiveness is a continuous variable. Classifying patients as "responders" and "non-responders" can be misleading and does not predict disease progression.


Related Articles

  • Deaths certitied as asthma and use of medical services: a national case-control study. Butland, B. K.; Anderson, H. R.; Sturdy, P. M.; Ayres, J. G.; Bland, J. M.; Harrison, B. D. W.; Peckitt, C.; Victor, C. R. // Thorax;Nov2005, Vol. 60 Issue 11, p909 

    Background: Studies have linked asthma death to either increased or decreased use of medical services. Methods: A population based case-control study of asthma deaths in 1994-8 was performed in 22 English, six Scottish, and five Welsh health authorities/boards. All 681 subjects who died were...

  • Breath-Actuated Nebulizer for Patients With Exacerbation of COPD: Efficiency and Cost. Hui-Ling Lin, Hui-Ling; Fink, James B. // Respiratory Care;Sep2012, Vol. 57 Issue 9, p1524 

    The author discusses a study by Haynes which examined the clinical response of the breath-actuated nebulizer (BAN) and small-volume nebulizer (SVN) on patients with exacerbation of chronic obstructive pulmonary disease (ECOPD). Improved inspiratory capacity (IC) and lower respiratory rate may be...

  • Inhaled Salmeterol: A Review of its Efficacy in Chronic Obstructive Pulmonary Disease. Jarvis, B.; Markham, A. // Drugs & Aging;2001, Vol. 18 Issue 6, p441 

    Inhaled salmeterol is a long-acting, selective β-adrenoceptor agonist bronchodilator. The drug has been compared with placebo, ipratropium bromide and oral theophylline in patients with chronic obstructive pulmonary disease (COPD) in randomised, clinical trials. Inhaled salmeterol 50µg...

  • New COPD guidelines urge use of drug still under study. Hitchens, Kathy // Drug Topics;8/18/2003, Vol. 147 Issue 16, pHSE7 

    Reports on the Global Initiative for Chronic Obstructive Lung Disease's issuance of an updated guidelines chronic obstructive pulmonary disease (COPD). Recommendation of bronchodilator tiotropium for maintenance COPD therapy; Reclassification of the staging of COPD.

  • Bronchodilator reversibility testing in COPD.  // Thorax;Feb2004, Vol. 59 Issue 2, p178 

    A letter to the editor is presented in response to the article "Bronchodilator reversibility testing in chronic obstruction pulmonary disease," by Calverley, Burge, Spencer et al. published in a 2003 issue of the journal.

  • Regular inhaled short acting β[sub 2] agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Ram, F.S.F.; Sestini, P. // Thorax;Jul2003, Vol. 58 Issue 7, p580 

    Background: Despite the lack of reversibility, patients with chronic obstructive pulmonary disease (COPD) often report symptomatic improvement with inhaled short acting β[sub 2] agonist bronchodilators (ISABAs) in the management of both stable and acute exacerbations of COPD. A review of the...

  • Bronchodilators in COPD and Arrhythmias.  // Clinical Cardiology Alert;Oct2012 Clinical Briefs in Primary Care, p19 

    The article presents a study by M. Wilchesky, et al published in a 2012 issue of "Chest" which compares the incidence of arrhythmia in chronic obstructive pulmonary disease subjects (COPD) that are users of ipatropium, beta-agonists, and methyhlxanthines versus those that do not use bronchodilators.

  • Bronchodilators in COPD and Arrhythmias.  // Critical Care Alert;Oct2012 Clinical Briefs in Primary Care, p19 

    The article summarizes a study by M. Wilchesky and colleagues that identifies chronic obstructive pulmonary disease (COPD) subjects and compares the incidence of arrhythmia in new users of bronchodilators and non-users, finding little absolute risk increase following the use of bronchodilators.

  • Stable copd management in relation to the GOLD: Experience at a university hospital. Durán, Diana; Vargas, Olga Cecilia // Colombia Medica;oct-dic2008, Vol. 39 Issue 4, p337 

    Introduction: This paper presents a prospective and descriptive study discussing the outpatient care plan in a public hospital in Bogotá for patients with stable COPD according with the GOLD recommendations. The paper presents as well the influence of factors such as education,...


Read the Article


Sign out of this library

Other Topics